Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002359
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Multicenter Double-Blind Phase III Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen Remune Compared to Incomplete Freunds Adjuvant IFA Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 CellsmicroL Rega
Sponsor:
The Immune Response Corporation
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Multicenter Double-Blind Phase III Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen Remune Compared to Incomplete Freunds Adjuvant IFA Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 CellsmicroL Regardless of Concomitant HIV Therapies
Status:
COMPLETED
Status Verified Date:
1997-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the effect of HIV-1 immunogen Remune on AIDS-free survival defined as the time prior to development of an AIDS-defining condition or death
Detailed Description:
Patients receive 10 units of HIV-1 immunogen in IFA or IFA alone every 12 weeks then are followed for 104-148 weeks
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 806 | None | None | None |